has been cited by the following article(s):
|
[1]
|
Improved metabolic efficacy of a dual amylin and calcitonin receptor agonist when combined with semaglutide or empagliflozin
|
|
European Journal of …,
2023 |
|
|
|
|
[2]
|
Efeitos colaterais da liraglutida em pessoas não diabéticas: uma revisão integrativa da literatura: Side effects of liraglutide in non-diabetic people: an integrative …
|
|
Brazilian Journal of …,
2022 |
|
|
|
|
[3]
|
The role of medicinal and aromatic plants against obesity and arthritis: A review
|
|
Nutrients,
2022 |
|
|
|
|
[4]
|
Dietary supplements and bariatric surgery
|
|
Critical reviews in …,
2022 |
|
|
|
|
[5]
|
A GLP‐1/glucagon (GCG)/CCK2 receptors tri‐agonist provides new therapy for obesity and diabetes
|
|
British Journal of …,
2022 |
|
|
|
|
[6]
|
Liraglutide for Weight Management
|
|
2021 |
|
|
|
|
[7]
|
Diagnostic Approach to Lymphadenopathy in children
|
|
2021 |
|
|
|
|
[8]
|
Liraglutide for Weight Management, Critical Analysis of Efficacy and Side effects in Non diabetic, individuals with obesity: A Comprehensive Systematic Review.
|
|
2021 |
|
|
|
|
[9]
|
Propuesta de mejora del proceso de pronósticos de demanda para productos de innovación de la compañía farmacéutica XXX.
|
|
2021 |
|
|
|
|
[10]
|
30 Drug Regimen and Intragastric Balloon: Pre, Post, During, Combined
|
|
2020 |
|
|
|
|
[11]
|
Drug Regimen and Intragastric Balloon: Pre, Post, During, Combined
|
|
2020 |
|
|
|
|
[12]
|
Metabolic dynamics of human Sertoli cells are differentially modulated by physiological and pharmacological concentrations of GLP-1
|
|
Toxicology and Applied Pharmacology,
2019 |
|
|
|
|
[1]
|
The Role of Medicinal and Aromatic Plants against Obesity and Arthritis: A Review
Nutrients,
2022
DOI:10.3390/nu14050985
|
|
|
|
|
[2]
|
Physical activity and obesity spectrum disorders in post-bariatric surgery patients: A systematic review and Meta-analysis
Critical Reviews in Food Science and Nutrition,
2022
DOI:10.1080/10408398.2022.2056868
|
|
|
|
|
[3]
|
A GLP‐1/glucagon (GCG)/CCK
2
receptors tri‐agonist provides new therapy for obesity and diabetes
British Journal of Pharmacology,
2022
DOI:10.1111/bph.15860
|
|
|
|
|
[4]
|
A GLP‐1/glucagon (GCG)/CCK2 receptors tri‐agonist provides new therapy for obesity and diabetes
British Journal of Pharmacology,
2022
DOI:10.1111/bph.15860
|
|
|
|